Objective: The excess of visceral adipose tissue might hinder and delay immune response. How people with abdominal obesity (AO) will respond to mRNA vaccines against SARS-CoV-2 is yet to be established. We evaluated SARS-CoV-2 specific antibody responses after the first and second dose of the BNT162b2 mRNA vaccine comparing the response of individuals with AO to those without, discerning between individuals with or without prior infection. Methods: IgG neutralizing antibodies against the Trimeric-complex (IgG-TrimericS) were measured at four time points: at baseline, at day 21 after vaccine dose 1, at one and three months after dose 2. Nucleocapsid antibodies were assessed to detect prior SARS-CoV-2 infection. Waist circumference was measured to determine AO. Results: Between the first and third month after vaccine dose 2, the drop in IgG-TrimericS levels was more remarkable in individuals with AO compared to those without AO (2.44 fold [95%CI: 2.22-2.63] vs 1.82 fold [95%CI: 1.69-1.92], respectively, p<0.001). Multivariable linear regression confirmed this result after inclusion of assessed confounders (p<0.001). Conclusions: The waning antibody levels in individuals with AO may further support recent recommendations to offer booster vaccines to adults with high-risk medical conditions including obesity and particularly to those with more prevalent abdominal obesity phenotype.

Antibody responses to BNT162b2 mRNA vaccine: infection‐naïve individuals with abdominal obesity warrant attention / A.E. Malavazos, S. Basilico, G. Iacobellis, V. Milani, R. Cardani, F. Boniardi, C. Dubini, I. Prandoni, G. Capitanio, L.V. Renna, S. Boveri, R. Rigolini, M. Carrara, G. Spuria, T. Cuppone, A. D’Acquisto, L. Carpinelli, M. Sacchi, L. Morricone, F. Secchi, E. Costa, L. Menicanti, E. Nisoli, M. Carruba, F. Ambrogi, M.M. Corsi Romanelli. - In: OBESITY. - ISSN 1930-7381. - (2021). [Epub ahead of print] [10.1002/oby.23353]

Antibody responses to BNT162b2 mRNA vaccine: infection‐naïve individuals with abdominal obesity warrant attention

A.E. Malavazos
Primo
;
S. Basilico
Secondo
;
R. Cardani;F. Boniardi;L.V. Renna;M. Carrara;G. Spuria;T. Cuppone;L. Carpinelli;F. Secchi;E. Costa;E. Nisoli;M. Carruba;F. Ambrogi
Penultimo
;
M.M. Corsi Romanelli
Ultimo
2021

Abstract

Objective: The excess of visceral adipose tissue might hinder and delay immune response. How people with abdominal obesity (AO) will respond to mRNA vaccines against SARS-CoV-2 is yet to be established. We evaluated SARS-CoV-2 specific antibody responses after the first and second dose of the BNT162b2 mRNA vaccine comparing the response of individuals with AO to those without, discerning between individuals with or without prior infection. Methods: IgG neutralizing antibodies against the Trimeric-complex (IgG-TrimericS) were measured at four time points: at baseline, at day 21 after vaccine dose 1, at one and three months after dose 2. Nucleocapsid antibodies were assessed to detect prior SARS-CoV-2 infection. Waist circumference was measured to determine AO. Results: Between the first and third month after vaccine dose 2, the drop in IgG-TrimericS levels was more remarkable in individuals with AO compared to those without AO (2.44 fold [95%CI: 2.22-2.63] vs 1.82 fold [95%CI: 1.69-1.92], respectively, p<0.001). Multivariable linear regression confirmed this result after inclusion of assessed confounders (p<0.001). Conclusions: The waning antibody levels in individuals with AO may further support recent recommendations to offer booster vaccines to adults with high-risk medical conditions including obesity and particularly to those with more prevalent abdominal obesity phenotype.
Abdominal obesity; BNT162b2 mRNA vaccine; IgG-TrimericS; SARS-CoV-2; antibody response
Settore MED/13 - Endocrinologia
30-nov-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
Obesity - 2021 - Malavazos - Antibody responses to BNT162b2 mRNA vaccine infection‐na ve individuals with abdominal.pdf

Open Access dal 01/12/2022

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 8.37 MB
Formato Adobe PDF
8.37 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/888307
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 14
social impact